Deflazacort: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Kiran Singh (talk | contribs)
nocaptcha, Administrators
24,170 edits
No edit summary
Kiran Singh (talk | contribs)
nocaptcha, Administrators
24,170 edits
No edit summary
Line 4: Line 4:
| verifiedrevid = 447631837
| verifiedrevid = 447631837
| IUPAC_name = (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′''H''-pregna-1,4-dieno[17,16-''d'']oxazole-3,20-dione
| IUPAC_name = (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′''H''-pregna-1,4-dieno[17,16-''d'']oxazole-3,20-dione
| image ={{Drugbox
| image = Deflazacort structure.svg
| Verifiedfields = changed
 
| Watchedfields = changed
| verifiedrevid = 447631837
| IUPAC_name = (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′''H''-pregna-1,4-dieno[17,16-''d'']oxazole-3,20-dione
| image = Deflazacort structure.png
<!--Clinical data-->
<!--Clinical data-->
| tradename =   
| tradename =   
Line 68: Line 64:




{{Glucocorticoids}}
{{Glucocorticoidics}}


[[Category:Glucocorticoids]]
[[Category:Glucocorticoids]]
[[Category:Prodrugs]]
[[Category:Prodrugs]]
[[Category:Oxazolines]]
[[Category:Acetate esters]]




 
{{systemic-hormonal-drug-stub}}
 
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|deflazacort}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL        / P      / POM / CD -->
| legal_US = <!-- OTC                  / Rx-only  -->
| legal_status = 
| routes_of_administration = Oral
 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 40%
| metabolism = By plasma [[esterase]]s, to active metabolite
| elimination_half-life = 1.1–1.9 hours (metabolite)
| excretion = [[Kidney|Renal]] (70%) and fecal (30%)
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 14484-47-0
| ATC_prefix = H02
| ATC_suffix = AB13
| PubChem = 26709
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201891
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = KR5YZ6AE4B
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03671
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 164861
|  smiles = O=C(OCC(=O)[C@]25/N=C(\O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C)C
|  InChI = 1/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
|  InChIKey = FBHSPRKOSMHSIF-GRMWVWQJBC
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = FBHSPRKOSMHSIF-GRMWVWQJSA-N
 
<!--Chemical data-->
| C=25 | H=31 | N=1 | O=6
| molecular_weight = 441.517 g/mol
}}
__Notoc__
{{SI}}
{{CMG}}
==Overview==
 
'''Deflazacort''' is a [[glucocorticoid]] used as an [[anti-inflammatory]] and [[immunosuppressant]].
 
Deflazacort is an inactive [[prodrug]] which is [[drug metabolism|metabolized]] rapidly to the active drug 21-desacetyldeflazacort.<ref>{{cite journal | pmid = 7494809 | year = 1995 | last1 = Möllmann | first1 = H | last2 = Hochhaus | first2 = G | last3 = Rohatagi | first3 = S | last4 = Barth | first4 = J | last5 = Derendorf | first5 = H | title = Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone | volume = 12 | issue = 7 | pages = 1096–100 | journal = Pharmaceutical research }}</ref> Its potency is around 70–90% that of [[prednisone]].<ref name="eMC"/>
 
It is sold in [[Bangladesh]] as Xalcort, marketed by Beacon Pharmaceuticals Limited, in the [[United Kingdom]] by [[Shire plc|Shire]] under the trade name Calcort;<ref name="eMC">{{cite web | url = http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=20915 | title = Calcort | date = June 11, 2008 | publisher = electronic Medicines Compendium}} Retrieved on October 28, 2008.</ref> in [[Brazil]] as Cortax, Decortil, and Deflanil; in India as MOAID, Defolet(Roussette), DFZ, Decotaz, and DefZot; in Panama as Zamen, Spain as Zamene and in Honduras as Flezacor.<ref name=Centralx>{{cite web | url = http://www.bulas.med.br/index.pl?C=A&V=66506F737449443D39333933266163743D73686F7752656164436F6D6D656E7473<!--convenience link--> | title = Substâncias: DEFLAZACORT | year = 2008 | publisher = Centralx|language=pt}} Retrieved on October 28, 2008.</ref> It is not available in the United States. In January 2015, the FDA granted fast track status to Marathon Pharmaceuticals to pursue approval of deflazacort as a potential treatment for Duchenne muscular dystrophy. The company expects to make deflazacort available in the United States in 2016. <ref>http://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1</ref>
 
==References==
{{Reflist|2}}
 
 
 
[[Category:Glucocorticoids]]
[[Category:Prodrugs]]

Revision as of 18:44, 8 April 2015

Deflazacort
File:Deflazacort structure.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Pharmacokinetic data
Protein binding40%
MetabolismBy plasma esterases, to active metabolite
Elimination half-life1.1–1.9 hours (metabolite)
ExcretionRenal (70%) and fecal (30%)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC25H31NO6
Molar mass441.517 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.

Deflazacort is an inactive prodrug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.[1] Its potency is around 70–90% that of prednisone.[2]

It is sold in Bangladesh as Xalcort, marketed by Beacon Pharmaceuticals Limited, in the United Kingdom by Shire under the trade name Calcort;[2] in Brazil as Cortax, Decortil, and Deflanil; in India as MOAID, Defolet(Roussette), DFZ, Decotaz, and DefZot; in Panama as Zamen, Spain as Zamene and in Honduras as Flezacor.[3] It is not available in the United States. In January 2015, the FDA granted fast track status to Marathon Pharmaceuticals to pursue approval of deflazacort as a potential treatment for Duchenne muscular dystrophy. The company expects to make deflazacort available in the United States in 2016. [4]

References

  1. ↑ Möllmann, H; Hochhaus, G; Rohatagi, S; Barth, J; Derendorf, H (1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical research. 12 (7): 1096–100. PMID 7494809.
  2. ↑ 2.0 2.1 "Calcort". electronic Medicines Compendium. June 11, 2008. Retrieved on October 28, 2008.
  3. ↑ "Substâncias: DEFLAZACORT" (in português). Centralx. 2008. Retrieved on October 28, 2008.
  4. ↑ http://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1


Template:Glucocorticoids


Template:Systemic-hormonal-drug-stub

Retrieved from "https://www.wikidoc.org/index.php?title=Deflazacort&oldid=1084950"